Ensysce Biosciences to Present at Fierce New Product Planning Summit 2023

Ensysce Biosciences, a clinical-stage company focused on improving prescription drug safety, has announced its participation in the upcoming Fierce New Product Planning Summit 2023. The event, taking place in Boston, MA on October 16 and 17, will provide a platform for industry professionals to discuss and explore best practices for launching new drug products.

Geoff Birkett, the Chief Commercial Officer of Ensysce, will chair the meeting and deliver the opening remarks on Monday, October 16. He will also present a case study on Tuesday, October 17, highlighting the company’s approach to launching a new drug product. With his extensive experience in the pain, addiction, and neuroscience areas, Birkett has played a pivotal role in developing and launching groundbreaking medicines.

Ensysce is currently preparing for the launch of its first product in a new class of analgesics called PF614. The company’s portfolio is designed to provide innovative therapies for severe pain while addressing the challenges of prescription drug abuse and overdose. By leveraging their proprietary technology platforms, Ensysce aims to develop tamper-proof treatment options that minimize the risk of abuse and overdose.

The Fierce New Product Planning Summit is the premier conference dedicated to the new product planning role and related functions in the life science industry. It offers a unique opportunity for professionals to make informed, value-based, and data-driven decisions about products in the pipeline. Attendees will explore tailored product commercialization strategies and learn how to utilize various resources effectively.

Ensysce Biosciences is committed to developing safer prescription drugs through its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms. These platforms provide tamper-proof options for pain treatment, aiming to minimize the risk of drug abuse and overdose. The company’s products are expected to offer safer alternatives for patients suffering from severe pain and help prevent medication abuse-related deaths.

For more information about Ensysce Biosciences and its innovative approach to prescription drug safety, please visit www.ensysce.com.